TY - JOUR
T1 - Oxidative Stress and Menopausal Status
T2 - The Coronary Artery Risk Development in Young Adults Cohort Study
AU - Heravi, Amir S.
AU - Michos, Erin D.
AU - Zhao, Di
AU - Ambale-Venkatesh, Bharath
AU - Doria De Vasconcellos, Henrique
AU - Lloyd-Jones, Donald
AU - Schreiner, Pamela J.
AU - Reis, Jared P.
AU - Wu, Colin
AU - Lewis, Cora E.
AU - Shikany, James M.
AU - Sidney, Stephen
AU - Guallar, Eliseo
AU - Ndumele, Chiadi E.
AU - Ouyang, Pamela
AU - Hoogeveen, Ron C.
AU - Lima, Joao A.C.
AU - Vaidya, Dhananjay
AU - Post, Wendy S.
N1 - Publisher Copyright:
© Copyright 2022, Mary Ann Liebert, Inc., publishers 2022.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Background: Low endogenous estrogen concentrations after menopause may contribute to higher oxidative stress and greater cardiovascular disease (CVD) risk. However, differences in oxidative stress between similarly aged premenopausal and postmenopausal women are not well-characterized on a population level. We hypothesized that urinary isoprostane concentrations, a standard measure of systemic oxidative stress, are higher in women who have undergone menopause compared to premenopausal women. Methods and Results: We examined differences in urinary 8-isoprostane (iPF2α-III) and 2,3-dinor-8-isoprostane (iPF2α-III-M) indexed to urinary creatinine between 279 postmenopausal and 196 premenopausal women in the Coronary Artery Risk Development in Young Adults (CARDIA) study, using linear regression with progressive adjustment for sociodemographic factors and traditional CVD risk factors. Unadjusted iPF2α-III-M concentrations were higher among postmenopausal compared to premenopausal women (Median [25th, 75th percentile]: 1762 [1178, 2974] vs. 1535 [1067, 2462] ng/g creatinine; p = 0.01). Menopause was associated with 25.5% higher iPF2α-III-M (95% confidence interval [6.5-47.9]) adjusted for age, race, college education, and field center. Further adjustments for tobacco use (21.2% [2.9-42.6]) and then CVD risk factors (18.8% [0.1-39.6]) led to additional partial attenuation. Menopause was associated with higher iPF2α-III in Black but not White women. Conclusions: We conclude that postmenopausal women had higher oxidative stress, which may contribute to greater CVD risk. ClinicalTrials.gov Identifier: NCT00005130.
AB - Background: Low endogenous estrogen concentrations after menopause may contribute to higher oxidative stress and greater cardiovascular disease (CVD) risk. However, differences in oxidative stress between similarly aged premenopausal and postmenopausal women are not well-characterized on a population level. We hypothesized that urinary isoprostane concentrations, a standard measure of systemic oxidative stress, are higher in women who have undergone menopause compared to premenopausal women. Methods and Results: We examined differences in urinary 8-isoprostane (iPF2α-III) and 2,3-dinor-8-isoprostane (iPF2α-III-M) indexed to urinary creatinine between 279 postmenopausal and 196 premenopausal women in the Coronary Artery Risk Development in Young Adults (CARDIA) study, using linear regression with progressive adjustment for sociodemographic factors and traditional CVD risk factors. Unadjusted iPF2α-III-M concentrations were higher among postmenopausal compared to premenopausal women (Median [25th, 75th percentile]: 1762 [1178, 2974] vs. 1535 [1067, 2462] ng/g creatinine; p = 0.01). Menopause was associated with 25.5% higher iPF2α-III-M (95% confidence interval [6.5-47.9]) adjusted for age, race, college education, and field center. Further adjustments for tobacco use (21.2% [2.9-42.6]) and then CVD risk factors (18.8% [0.1-39.6]) led to additional partial attenuation. Menopause was associated with higher iPF2α-III in Black but not White women. Conclusions: We conclude that postmenopausal women had higher oxidative stress, which may contribute to greater CVD risk. ClinicalTrials.gov Identifier: NCT00005130.
KW - cardiovascular risk factors
KW - isoprostanes
KW - menopause
KW - oxidative stress
KW - urinary isoprostanes
UR - http://www.scopus.com/inward/record.url?scp=85134509982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134509982&partnerID=8YFLogxK
U2 - 10.1089/jwh.2021.0248
DO - 10.1089/jwh.2021.0248
M3 - Article
C2 - 35675673
AN - SCOPUS:85134509982
SN - 1540-9996
VL - 31
SP - 1057
EP - 1065
JO - Journal of Women's Health
JF - Journal of Women's Health
IS - 7
ER -